This might slow down AGEN a bit -- geez, they just raised a wad a few months ago -- just what are they burning their dough on?
>>WASHINGTON, April 29 (Reuters) - Biotechnology firm Antigenics Inc. (NasdaqNM:AGEN - News) filed on Tuesday with the Securities and Exchange Commission (News - Websites) to periodically sell up to $100 million in debt securities and common and preferred stock.
The New York City-based company, which is developing products to treat cancers, infectious diseases and autoimmune disorders, plans to use the net proceeds for general corporate purposes, which may include working capital and capital expenditures.
The proceeds may also be used for research and development, clinical trials, acquisitions of new technologies, and investments, it said in the shelf registration filing.
Under such a filing, a company may sell securities in one or more separate offerings with the size, price and terms to be determined at the time of sale.
Antigenics shares rose 7 cents to close at $10.07 on Nasdaq. <<
Cheers, Tuck |
